Education
About Us
Working with TipRanks
Follow Us
Basilea Pharmaceutica (CH:BSLN)
:BSLN
BSLN Stock Chart & Stats
CHF56.50
CHF0.45(0.96%)
At close: 4:00 PM EST
CHF56.50
CHF0.45(0.96%)
Day’s Range― - ―
52-Week RangeCHF37.50 - CHF59.70
Previous CloseN/A
Volume30.09K
Average Volume (3M)41.01K
Market Cap
CHF667.52M
Enterprise ValueCHF669.03M
Total Cash (Recent Filing)CHF128.37M
Total Debt (Recent Filing)CHF96.79M
Price to Earnings (P/E)9.4
Beta1.08
Next Earnings
Feb 17, 2026EPS Estimate
1.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.26
Shares Outstanding13,320,282
10 Day Avg. Volume32,790
30 Day Avg. Volume41,007
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)6.17
Price to Sales (P/S)2.40
P/FCF Ratio6.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF87.00Price Target Upside53.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-driven Discovery PartnershipPartnership with Phare Bio to apply artificial intelligence could accelerate discovery and development of novel antibiotics, strengthening Basilea's early-stage pipeline.
Fosmanogepix Successor PotentialFosmanogepix as a potential successor to Cresemba could secure regulatory approvals in multiple territories ahead of Cresemba sales decline, offering a pathway to sustain long-term antifungal revenue.
Global Cresemba Commercial ReachCresemba's approval and marketing in more than 70 countries and solid commercial momentum support sales-based milestone payments that enhance revenue visibility for the antifungal franchise.
Bears Say
Clinical Development Risk For FosmanogepixSetbacks in clinical development of fosmanogepix would jeopardize the planned successor strategy and could materially slow Basilea's growth trajectory.
Partner Execution Risk For Marketed DrugsDependence on partners to optimize isavuconazole and ceftobiprole globally creates execution risk that could limit revenue capture if partners fail to commercialize effectively.
Portfolio Concentration And Milestone UncertaintyConcentration of value in a small number of antifungal assets and reliance on sales-triggered milestones could increase financial volatility if one product underperforms or misses targets.
Basilea Pharmaceutica News
BSLN FAQ
What was Basilea Pharmaceutica’s price range in the past 12 months?
Basilea Pharmaceutica lowest stock price was CHF37.50 and its highest was CHF59.70 in the past 12 months.
What is Basilea Pharmaceutica’s market cap?
Basilea Pharmaceutica’s market cap is CHF667.52M.
When is Basilea Pharmaceutica’s upcoming earnings report date?
Basilea Pharmaceutica’s upcoming earnings report date is Feb 17, 2026 which is in 12 days.
How were Basilea Pharmaceutica’s earnings last quarter?
Basilea Pharmaceutica released its earnings results on Aug 19, 2025. The company reported CHF1.26 earnings per share for the quarter, missing the consensus estimate of CHF2.03 by -CHF0.77.
Is Basilea Pharmaceutica overvalued?
According to Wall Street analysts Basilea Pharmaceutica’s price is currently Undervalued.
Does Basilea Pharmaceutica pay dividends?
Basilea Pharmaceutica pays a Notavailable dividend of CHF5 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here
What is Basilea Pharmaceutica’s EPS estimate?
Basilea Pharmaceutica’s EPS estimate is 1.64.
How many shares outstanding does Basilea Pharmaceutica have?
Basilea Pharmaceutica has 13,320,282 shares outstanding.
What happened to Basilea Pharmaceutica’s price movement after its last earnings report?
Basilea Pharmaceutica reported an EPS of CHF1.26 in its last earnings report, missing expectations of CHF2.03. Following the earnings report the stock price went down -7.561%.
Which hedge fund is a major shareholder of Basilea Pharmaceutica?
Currently, no hedge funds are holding shares in CH:BSLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
BSLN Stock 12 Month Forecast
Average Price Target
CHF87.00
▲(53.98% Upside)
Technical Analysis
Molecular Partners AG
―
Idorsia Ltd
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---